Oncology — Pharmacokinetics Simulators
48 interactive PK simulators available for oncology drugs.
About Oncology Pharmacokinetics
Oncology pharmacokinetics encompasses the study of drug absorption, distribution, metabolism, and elimination of anti-cancer agents. Understanding PK properties is critical for optimizing dosing of chemotherapy, targeted therapies, immune checkpoint inhibitors, and antibody-drug conjugates to maximize efficacy while minimizing toxicity.
Small Molecule
Compare →Ibrance (Palbociclib)
HR+/HER2- metastatic breast cancer
Imatinib
CML / GIST
Imbruvica (Ibrutinib)
Chronic lymphocytic leukemia
Infigratinib
Cholangiocarcinoma
Lynparza (Olaparib)
BRCA-mutated ovarian cancer
Oncology Dose Selection Tool
Solid Tumors
Pomalyst (Pomalidomide)
Multiple myeloma
Revlimid (Lenalidomide)
Multiple myeloma
Tagrisso (Osimertinib)
EGFR-mutated non-small cell lung cancer
Verzenio (Abemaciclib)
HR+/HER2- metastatic breast cancer
Xtandi (Enzalutamide)
Metastatic castration-resistant prostate cancer
mAb
Compare →Darzalex (Daratumumab)
Multiple myeloma
Imfinzi (Durvalumab)
Non-small cell lung cancer
Keytruda (Pembrolizumab)
Melanoma and non-small cell lung cancer
Opdivo (Nivolumab)
Melanoma and non-small cell lung cancer
Perjeta (Pertuzumab)
HER2-positive breast cancer
T-cell Engager
Hematologic Malignancies
Tecentriq (Atezolizumab)
Non-small cell lung cancer
Trastuzumab
HER2+ Breast Cancer
Trastuzumab
HER2+ Breast Cancer
Tumor Exposure Analysis
Solid Tumors
Antibody-Drug Conjugate (ADC)
Compare →ADCs
HER2-positive breast cancer, NSCLC, gastric/GEJ cancer
Dato
TROP2-positive metastatic breast cancer
Datroway
Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload
Enhertu
HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC
PBPK-PD Topo1-Based ADC
Solid tumors (breast, lung, gastric, colorectal cancer)
PBPK-PD Topo1-Based ADC
Solid tumors (breast, lung, gastric, colorectal cancer)
PBPK-PD of ADCs
Trodelvy
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
Antimetabolite
Compare →PARP Inhibitor
Compare →PROTAC
Compare →ADC
Anthracycline
Anti-HER2 Monoclonal Antibody
Antibody-Drug Conjugate
Fluoropyrimidine / Oral Prodrug
Monoclonal Antibody
Monoclonal Antibody (Anti-HER2)
Multikinase Inhibitor (TKI)
PARP inhibitor
PD-1 inhibitor
Platinum
Taxane
Taxane (Microtubule Stabilizer)
Disclaimer: These simulators are for educational and research purposes only. Pharmacokinetic models are based on published literature and may not reflect individual patient variability. Not intended for clinical decision-making. Always consult prescribing information and clinical guidelines.